Research Articles | Page 80 | Aplastic Anemia & MDS International Foundation Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Eltrombopag for refractory severe aplastic anemia: dosing, duration, long term outcomes and clonal evolution Apr 2019 Blood aplastic anemia
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) Jun 2023 Journal of Clinical Oncology myelodysplastic syndromes (MDS)
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) Oct 2023 Journal of Clinical Oncology myelodysplastic syndromes (MDS)
Eltrombopag and improved hematopoiesis in refractory aplastic anemia Jul 2012 N Engl J Med aplastic anemia
Eltrombopag Added to Standard Immunosuppression for Aplastic Anemia Apr 2017 N Engl J Med aplastic anemia
Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromes Jan 2017 Asia Pac J Clin Oncol myelodysplastic syndromes (MDS)
Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study Jul 2016 Int J Hematol aplastic anemia
Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis Dec 2023 Therapeutic Advances in Hematology paroxysmal nocturnal hemoglobinuria (PNH)
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study Jul 2023 American Journal of Hematology paroxysmal nocturnal hemoglobinuria (PNH)
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial Jun 2023 Lancet myelodysplastic syndromes (MDS)
Share with addtoany.com.